176 related articles for article (PubMed ID: 37883181)
1. Gasdermin C sensitizes tumor cells to PARP inhibitor therapy in cancer models.
Wang S; Chang CW; Huang J; Zeng S; Zhang X; Hung MC; Hou J
J Clin Invest; 2024 Jan; 134(1):. PubMed ID: 37883181
[TBL] [Abstract][Full Text] [Related]
2. PARP1 inhibitors induce pyroptosis via caspase 3-mediated gasdermin E cleavage.
Kim C; Wang XD; Jang S; Yu Y
Biochem Biophys Res Commun; 2023 Feb; 646():78-85. PubMed ID: 36706709
[TBL] [Abstract][Full Text] [Related]
3. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
4. Detection of Gasdermin C-Mediated Cancer Cell Pyroptosis.
Hou J; Wang S; Miao R; Zhang X; Hung MC
Methods Mol Biol; 2023; 2641():135-146. PubMed ID: 37074647
[TBL] [Abstract][Full Text] [Related]
5. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
7. LINC00511/hsa-miR-573 axis-mediated high expression of Gasdermin C associates with dismal prognosis and tumor immune infiltration of breast cancer.
Sun K; Chen RX; Li JZ; Luo ZX
Sci Rep; 2022 Aug; 12(1):14788. PubMed ID: 36042287
[TBL] [Abstract][Full Text] [Related]
8. Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells.
Kawanishi M; Fujita M; Karasawa K
Breast Cancer (Auckl); 2022; 16():11782234221080553. PubMed ID: 35340889
[TBL] [Abstract][Full Text] [Related]
9. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis.
Hou J; Zhao R; Xia W; Chang CW; You Y; Hsu JM; Nie L; Chen Y; Wang YC; Liu C; Wang WJ; Wu Y; Ke B; Hsu JL; Huang K; Ye Z; Yang Y; Xia X; Li Y; Li CW; Shao B; Tainer JA; Hung MC
Nat Cell Biol; 2020 Oct; 22(10):1264-1275. PubMed ID: 32929201
[TBL] [Abstract][Full Text] [Related]
10. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
11. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation.
Hu X; Zhao M; Bai M; Xue Z; Wang F; Zhu Z; Yu J; Yue J
Cancer Lett; 2024 Apr; 586():216676. PubMed ID: 38278469
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
Chu YY; Yam C; Yamaguchi H; Hung MC
J Biomed Sci; 2022 Oct; 29(1):86. PubMed ID: 36284291
[TBL] [Abstract][Full Text] [Related]
13. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
Cerrato A; Morra F; Celetti A
J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
[TBL] [Abstract][Full Text] [Related]
14. Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.
Wooten J; Mavingire N; Damar K; Loaiza-Perez A; Brantley E
J Cell Physiol; 2023 Aug; 238(8):1625-1640. PubMed ID: 37042191
[TBL] [Abstract][Full Text] [Related]
15. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Kim DS; Camacho CV; Kraus WL
Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
Zhu X; Chen L; Huang B; Li X; Yang L; Hu X; Jiang Y; Shao Z; Wang Z
J Exp Clin Cancer Res; 2021 Apr; 40(1):122. PubMed ID: 33832512
[TBL] [Abstract][Full Text] [Related]
17. MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer.
Bustos MA; Yokoe T; Shoji Y; Kobayashi Y; Mizuno S; Murakami T; Zhang X; Sekhar SC; Kim S; Ryu S; Knarr M; Vasilev SA; DiFeo A; Drapkin R; Hoon DSB
Cell Biosci; 2023 Nov; 13(1):200. PubMed ID: 37932806
[TBL] [Abstract][Full Text] [Related]
18. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
[No Abstract] [Full Text] [Related]
19. Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer.
Yordanova M; Hubert A; Hassan S
Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959671
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-Ribose) Polymerase-1 Inhibitors Drug Discovery, Design, and Development as Anticancer Agents from Past to Present: A Mini-Review.
AlGhamdi A; AlMubayedh H
Mini Rev Med Chem; 2022; 22(12):1597-1606. PubMed ID: 34587882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
